Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 762
- Registration Number
- NCT00630032
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇫🇷Centre Hospitalier Docteur Duchenne, Boulogne Sur Mer, France
🇺🇸CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Azienda Ospedaliero-Universitaria di Modena
- Target Recruit Count
- 2500
- Registration Number
- NCT00629278
- Locations
- 🇮🇹
Ospedal San Andrea, Vercelli, Italy
🇮🇹Ospedale Civile di Ivrea, Ivrea, Italy
🇮🇹Azienda Sanitaria Ospedale San Giovanni Battista Molinette di Torino, Turin, Italy
Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 86
- Registration Number
- NCT00628810
- Locations
- 🇫🇷
Hopital Ambroise Pare, Boulogne-Billancourt, France
🇫🇷Hopital Du Bocage, Dijon, France
🇫🇷Centre Hospitalier Departemental, La Roche Sur Yon, France
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 3509
- Registration Number
- NCT00625898
- Locations
- 🇺🇸
Peninsula Regional Oncology & Hematology, Salisbury, Maryland, United States
🇺🇸Associates in Oncology/Hematology, Rockville, Maryland, United States
🇺🇸The Office of Frederik Smith, Chevy Chase, Maryland, United States
Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies
- Conditions
- Peritoneal Cavity Cancer
- Interventions
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 17
- Registration Number
- NCT00625092
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
- Conditions
- Rectal Cancer
- Interventions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 13
- Registration Number
- NCT00611858
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Vanderbilt Medical Center, Nashville, Tennessee, United States
Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT00610948
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Target Recruit Count
- 1
- Registration Number
- NCT00609765
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 69
- Registration Number
- NCT00608205
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
- Conditions
- Pancreatic Cancer
- Interventions
- Biological: panitumumabDrug: capecitabineDrug: fluorouracilDrug: gemcitabine hydrochlorideRadiation: radiation therapy
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 52
- Registration Number
- NCT00601627
- Locations
- 🇺🇸
Great Falls Clinic - Main Facility, Great Falls, Montana, United States
🇺🇸Mid Dakota Clinic, PC, Bismarck, North Dakota, United States
🇺🇸Illinois CancerCare - Canton, Canton, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.